MUDr Nedal Omran
- Address
- Sramkova 3319/2a, 400 11 Ústí nad Labem, Czechia
MUDr Nedal Omran - Cardiovascular and Renal Research Center
MUDr Nedal Omran operates a specialized clinical research facility focused on advanced cardiovascular therapeutics and cardiorenal syndrome management. The center demonstrates particular expertise in evaluating novel treatment combinations for patients with complex comorbid conditions affecting both cardiac and renal systems.
- Heart failure management and therapeutic optimization
- Cardiorenal syndrome and chronic kidney disease complications
- Novel pharmacological combinations for cardiovascular protection
The facility is actively engaged in Phase III clinical investigations examining balcinrenone and dapagliflozin combination therapy for patients with chronic heart failure and impaired kidney function. Research efforts concentrate on reducing cardiovascular mortality and heart failure events through innovative therapeutic approaches, with particular emphasis on patients experiencing recent heart failure events who require intensive management of both cardiac and renal dysfunction.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MUDr Nedal Omran
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Balcinrenone and Dapagliflozin on Cardiovascular Outcomes in Heart Failure Patients with Renal Impairment: A Phase III Randomized, Double-Blind Study | AstraZeneca AB | Phase III | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Balcinrenone | 1 | Unknown | 2024-07-12 | 2024-07-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.